McKesson Corp (MCK) FinancialsMCKFinancialMcKesson Corp

McKesson Corp (MCK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is North American Pharmaceutical, accounting for 82.3% of total sales, equivalent to $86.77B. Other significant revenue streams include Oncology & Multispecialty and Medical-Surgical Solutions. Understanding this composition is critical for investors evaluating how MCK navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, McKesson Corp maintains a gross margin of 3.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.41%, while the net margin is 0.98%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MCK converts its operational activities into shareholder value.

In the context of the broader market, MCK competes directly with industry leaders such as COR and CAH. With a market capitalization of $103.82B, it holds a leading position in the sector. When comparing efficiency, MCK's gross margin of 3.50% stands against COR's 3.95% and CAH's 3.87%. Such benchmarking helps identify whether McKesson Corp is trading at a premium or discount relative to its financial performance.

McKesson reported a revenue of $403.4 billion for fiscal 2026, a 12% increase year-over-year, with adjusted EPS rising 18% to $39.11. The gross margin improved to 4.20% in the latest quarter, indicating better profitability.